Fortress Biotech Net Worth

Fortress Biotech Net Worth Breakdown

  FBIO
The net worth of Fortress Biotech is the difference between its total assets and liabilities. Fortress Biotech's net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Fortress Biotech's assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Fortress Biotech's net worth can be used as a measure of its financial health and stability which can help investors to decide if Fortress Biotech is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Fortress Biotech stock.

Fortress Biotech Net Worth Analysis

Fortress Biotech's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Fortress Biotech's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Fortress Biotech's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Fortress Biotech's net worth analysis. One common approach is to calculate Fortress Biotech's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Fortress Biotech's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Fortress Biotech's net worth. This approach calculates the present value of Fortress Biotech's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Fortress Biotech's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Fortress Biotech's net worth. This involves comparing Fortress Biotech's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Fortress Biotech's net worth relative to its peers.

Enterprise Value

34.26 Million

To determine if Fortress Biotech is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Fortress Biotech's net worth research are outlined below:
Fortress Biotech may become a speculative penny stock
Fortress Biotech had very high historical volatility over the last 90 days
Fortress Biotech has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 57.67 M. Net Loss for the year was (120.86 M) with profit before overhead, payroll, taxes, and interest of 2.14 M.
Fortress Biotech currently holds about 208.35 M in cash with (80.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.92.
Fortress Biotech has a very weak financial position based on the latest SEC disclosures
Roughly 21.0% of the company shares are held by company insiders
Latest headline from zacks.com: Ultragenyx Surges 5.1 percent Is This an Indication of Further Gains
Fortress Biotech uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Fortress Biotech. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Fortress Biotech's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Know Fortress Biotech's Top Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Fortress Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Fortress Biotech backward and forwards among themselves. Fortress Biotech's institutional investor refers to the entity that pools money to purchase Fortress Biotech's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Acadian Asset Management Llc2025-03-31
90.5 K
180 Wealth Advisors, Llc2025-03-31
87.5 K
Commonwealth Equity Services Inc2025-03-31
61.5 K
Integrated Wealth Concepts Llc2025-03-31
59.4 K
Cetera Investment Advisers2025-03-31
46.6 K
Weaver Consulting Group2025-03-31
46.4 K
Pfg Investments, Llc2025-03-31
45.3 K
Group One Trading, Lp2025-03-31
44.8 K
Two Sigma Investments Llc2025-03-31
44.8 K
Cambridge Invest Research Advisors, Inc.2025-03-31
M
Vanguard Group Inc2025-03-31
752.6 K
Note, although Fortress Biotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Follow Fortress Biotech's market capitalization trends

The company currently falls under 'Micro-Cap' category with a current market capitalization of 55.89 M.

Market Cap

91.9 Million

Project Fortress Biotech's profitablity

Last ReportedProjected for Next Year
Return On Tangible Assets(0.41)(0.43)
Return On Capital Employed(1.52)(1.59)
Return On Assets(0.32)(0.33)
Return On Equity(2.02)(2.12)
The company has Profit Margin (PM) of (0.71) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (1.7) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $1.7.
When accessing Fortress Biotech's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Fortress Biotech's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Fortress Biotech's profitability and make more informed investment decisions.

Evaluate Fortress Biotech's management efficiency

Fortress Biotech has return on total asset (ROA) of (0.3237) % which means that it has lost $0.3237 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.4625) %, meaning that it created substantial loss on money invested by shareholders. Fortress Biotech's management efficiency ratios could be used to measure how well Fortress Biotech manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of July 2025, Return On Tangible Assets is likely to drop to -0.43. In addition to that, Return On Capital Employed is likely to drop to -1.59. At this time, Fortress Biotech's Debt To Assets are very stable compared to the past year. As of the 13th of July 2025, Fixed Asset Turnover is likely to grow to 4.48, while Non Current Assets Total are likely to drop about 40.2 M.
Last ReportedProjected for Next Year
Book Value Per Share(0.08)(0.08)
Tangible Book Value Per Share(1.61)(1.53)
Enterprise Value Over EBITDA(0.58)(0.61)
Price Book Value Ratio 1.86  1.76 
Enterprise Value Multiple(0.58)(0.61)
Price Fair Value 1.86  1.76 
Enterprise Value54.8 M34.3 M
The operational strategies employed by Fortress Biotech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Enterprise Value Revenue
0.6712
Revenue
57.8 M
Quarterly Revenue Growth
0.008
Revenue Per Share
2.501
Return On Equity
(7.46)
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Fortress Biotech insiders, such as employees or executives, is commonly permitted as long as it does not rely on Fortress Biotech's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Fortress Biotech insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
David Jin over two months ago
Acquisition by David Jin of 5000 shares of Fortress Biotech at 1.2155 subject to Rule 16b-3
 
Lu Lucy over three months ago
Acquisition by Lu Lucy of 49383 shares of Fortress Biotech subject to Rule 16b-3
 
Lindsay Rosenwald over three months ago
Acquisition by Lindsay Rosenwald of 8133 shares of Fortress Biotech subject to Rule 16b-3
 
Lu Lucy over three months ago
Acquisition by Lu Lucy of 30000 shares of Fortress Biotech subject to Rule 16b-3
 
Lindsay Rosenwald over six months ago
Acquisition by Lindsay Rosenwald of 454153 shares of Fortress Biotech subject to Rule 16b-3
 
Rowinsky Eric K over six months ago
Disposition of 8000 shares by Rowinsky Eric K of Fortress Biotech at 4.31 subject to Rule 16b-3
 
Lindsay Rosenwald over six months ago
Acquisition by Lindsay Rosenwald of 1567515 shares of Fortress Biotech at 1.7 subject to Rule 16b-3
 
Lindsay Rosenwald over a year ago
Acquisition by Lindsay Rosenwald of 5000 shares of Fortress Biotech at 7.3942 subject to Rule 16b-3
 
Lindsay Rosenwald over a year ago
Acquisition by Lindsay Rosenwald of 20000 shares of Fortress Biotech at 1.6362 subject to Rule 16b-3
 
David Jin over a year ago
Acquisition by David Jin of 5000 shares of Fortress Biotech at 0.56 subject to Rule 16b-3
 
David Jin over a year ago
Disposition of tradable shares by David Jin of Fortress Biotech subject to Rule 16b-3
 
Lindsay Rosenwald over a year ago
Acquisition by Lindsay Rosenwald of 100000 shares of Fortress Biotech at 0.695 subject to Rule 16b-3
Fortress Biotech time-series forecasting models is one of many Fortress Biotech's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Fortress Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Fortress Biotech Earnings per Share Projection vs Actual

Fortress Biotech Corporate Management

Samuel BerryGeneral SecretaryProfile
Xiaoqin MDChief OfficerProfile
Robyn HunterEx OfficerProfile
Thomas SchaibleProject DiseaseProfile
When determining whether Fortress Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Fortress Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fortress Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fortress Biotech Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fortress Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
To learn how to invest in Fortress Stock, please use our How to Invest in Fortress Biotech guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fortress Biotech. If investors know Fortress will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fortress Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.13)
Revenue Per Share
2.501
Quarterly Revenue Growth
0.008
Return On Assets
(0.32)
Return On Equity
(7.46)
The market value of Fortress Biotech is measured differently than its book value, which is the value of Fortress that is recorded on the company's balance sheet. Investors also form their own opinion of Fortress Biotech's value that differs from its market value or its book value, called intrinsic value, which is Fortress Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fortress Biotech's market value can be influenced by many factors that don't directly affect Fortress Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fortress Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fortress Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fortress Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.